This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
HAYES, Inc. Sofosbuvir-velpatasvir for chronic HCV infection. Lansdale: HAYES, Inc. Directory Publication. 2016
Sofosbuvir-velpatasvir (Epclusa) is a "next-generation" once-daily direct-acting antiretroviral (DAA) combination oral regimen for the treatment of all 6 major hepatitis C virus (HCV) genotypes. The fixed-dose combination pill contains 400 mg of sofosbuvir and 100 mg of velpatasvir.
Rationale: Sofosbuvir-velpatasvir is intended to treat any genotype and subtype of HCV using an existing drug
with accepted efficacy, plus a new drug that is intended to improve efficacy by targeting HCV in a different way.
Relevant Questions: Does sofosbuvir-velpatasvir result in high rates of sustained virologic response (SVR) and low rates of treatment failure (i.e., virologic relapse)? How does sofosbuvir-velpatasvir compare with other treatments for HCV for increasing SVR rates, reducing treatment failure (i.e., virologic relapse) rates, or improving patient-oriented outcomes (e.g., quality of life)? What harms and complications are associated with sofosbuvir-velpatasvir? Have definitive patient selection criteria been established for sofosbuvir-velpatasvir for treatment of chronic HCV infection?
Subject indexing assigned by CRD
Carbamates; Hepatitis C, Chronic; Heterocyclic Compounds with 4 or More Rings; Humans; Sofosbuvir
Country of organisation
An English language summary is available.
Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: firstname.lastname@example.org
Date abstract record published